Bucindolol hydrochloride is under clinical development by ARCA biopharma and currently in Phase III for Atrial Fibrillation. According to GlobalData, Phase III drugs for Atrial Fibrillation have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bucindolol hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bucindolol hydrochloride overview

Bucindolol hydrochloride (Gencaro) is under development for the treatment of atrial fibrillation and atrial flutter. It is formulated as a capsule and administered orally. The drug candidate is a mild vasodilator and also acts by targeting beta adrenergic receptors. The drug candidate was also under development for the treatment of chronic heart failure.

ARCA biopharma overview

ARCA biopharma (ARCA), formerly Nuvelo is a company that develops genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment and prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. ARCA also develops AB171, a thiol-substituted isosorbide mononitrate for genetically targeted treatment of peripheral arterial disease and heart failure; and rNAPc2, a potential treatment for patients hospitalized with COVID-19. It provides medical treatment to the individual genetic characteristics of each patient and personalized medicine approach to drug development. The company works in partnership with universities to improve the health of cardiovascular patients. ARCA is headquartered in Westminster, Colorado, the US.

For a complete picture of Bucindolol hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.